Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) a

Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the

On Tuesday, Exagen (NASDAQ:XGN) discussed second-quarter financial results during its earnings call.

Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-

Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-

Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moder

Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healt

B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises

Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, averag

Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript

Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular se

Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estim

Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday'

Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 mill

Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly

CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of

CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of

Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markersDe

Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers D

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Ex

Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript

Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as ex

Exagen Inc. (XGN) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estim

Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 mil

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus

CARLSBAD, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of

Zimmer Biomet (ZBH) came out with quarterly earnings of $2.09 per share, beating the Zacks Consensus

CARLSBAD, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider o

Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and lowers the pri

Craig-Hallum analyst John Wilkin maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price ta

Keybanc analyst Paul Knight maintains Exagen (NASDAQ:XGN) with a Overweight and lowers the price

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which missed the analyst consensu

TD Cowen analyst Dan Brennan maintains Exagen (NASDAQ:XGN) with a Buy and lowers the price target

B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and lowers

B. Riley Securities analyst Anderson Schock reiterates Exagen (NASDAQ:XGN) with a Buy and raises

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.19) per share which missed the analyst consensu

Exagen (NASDAQ:XGN) affirms FY2025 sales outlook from $65.000 million-$70.000 million to $65.000 mil

Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the pri